Spectrum hits the reset button, slicing away 30% of its workforce in pivot around 2 lead assets

Kyle Blankenship

Covid-19 has been a rough go for many drugmakers, but few more so than Spectrum Pharmaceuticals, which has seen inspection delays and unwanted CRLs haunt …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Spectrum hits the reset button, slicing away 30% of its workforce in pivot around 2 lead assets

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Spec­trum hits the re­set but­ton, slic­ing away 30% of its work­force in piv­ot around 2 lead as­sets

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Spectrum hits the reset button, slicing away 30% of its workforce in pivot around 2 lead assets